EFFECT OF THE ALPHA-GLUCOSIDASE-INHIBITOR BAY-G-5421 ON BLOOD-GLUCOSE CONTROL OF SULFONYLUREA-TREATED DIABETICS AND INSULIN-TREATED DIABETICS

被引:84
作者
SACHSE, G [1 ]
WILLMS, B [1 ]
机构
[1] FACHKLIN DIABETES & STOFFWECHSELKRANKHEITEN,KIRCHBERG 21,D-3422 BAD LAUTERBERG,FED REP GER
关键词
α-glucosidase-inhibitor; blood glucose control; insulin-treated diabetics; sulphonylureatreated diabetics;
D O I
10.1007/BF01235884
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BAY-g-5421 is an α-glucosidase-inhibitor which inhibits intestinal absorption of carbohydrates. In a double-blind cross over study 12 diabetics taking sulphonylureas and 12 insulin-treated diabetics were treated additionally with BAY-g-5421 or a placebo for two seven day periods. In the pretreatment period and on the 7th and 14th day of the treatment periods serial blood glucose profiles were measured. In comparison to placebo BAY-g-5421 significantly lowered the mean (140 versus 157 mg/dl) and the maximal (192 versus 230 mg/dl) blood glucose values and the integrated blood glucose response (3112 versus 3421 mg/dl · 24 h) in the sulphonylurea-treated group as well as in the insulin-treated group (mean blood glucose 161 versus 192 mg/dl, maximal blood glucose 238 versus 283 mg/dl, integrated blood glucose response 3109 versus 3857 mg/dl · 24 h). The amplitude of glycaemic excursions was significantly decreased only in the sulphonylurea-treated group (96 versus 129 mg/dl), but not in the insulin-treated diabetics. No influence on routine liver function, renal function or haematological tests was observed. Side effects included hypoglycaemia in 3 patients of the insulin-treated group and meteorism in both groups. BAY-g-5421 could be a useful additional treatment for diabetic patients. © 1979 Springer-Verlag.
引用
收藏
页码:287 / 290
页数:4
相关论文
共 9 条
[1]  
CASPARY WF, 1978, LANCET, V1, P1231
[2]  
HILLEBRAND I, COMMUNICATION
[3]  
KEUP U, 1975, RECENT ADV OBESITY R, P412
[4]   GLUCOSIDASE INHIBITION - NEW APPROACH TO TREATMENT OF DIABETES, OBESITY, AND HYPERLIPOPROTEINEMIA [J].
PULS, W ;
KEUP, U ;
KRAUSE, HP ;
THOMAS, G ;
HOFFMEISTER, F .
NATURWISSENSCHAFTEN, 1977, 64 (10) :536-537
[5]   INFLUENCE OF AN ALPHA-AMYLASE INHIBITOR (BAY D 7791) ON BLOOD-GLUCOSE, SERUM-INSULIN AND NEFA IN STARCH LOADING TESTS IN RATS, DOGS AND MAN [J].
PULS, W ;
KEUP, U .
DIABETOLOGIA, 1973, 9 (02) :97-101
[6]   INHIBITION OF SUCRASE BY TRIS IN RAT AND MAN, DEMONSTRATED BY ORAL LOADING TESTS WITH SUCROSE [J].
PULS, W ;
KEUP, U .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1975, 24 (01) :93-98
[7]  
PULS W, 1975, RECENT ADV OBESITY R, P391
[8]   ALPHA-GLUCOSIDASE INHIBITORS - NEW COMPLEX OLIGOSACCHARIDES OF MICROBIAL ORIGIN [J].
SCHMIDT, DD ;
FROMMER, W ;
JUNGE, B ;
MULLER, L ;
WINGENDER, W ;
TRUSCHEIT, E ;
SCHAFER, D .
NATURWISSENSCHAFTEN, 1977, 64 (10) :535-536
[9]   IMPROVED METABOLIC PROFILES IN INSULIN-TREATED DIABETIC-PATIENTS GIVEN AN ALPHA-GLUCOSIDEHYDROLASE INHIBITOR [J].
WALTON, RJ ;
SHERIF, IT ;
NOY, GA ;
ALBERTI, KGM .
BRITISH MEDICAL JOURNAL, 1979, 1 (6158) :220-221